RNA polymerase III subunit G pseudogene 2Genealiases: []
Q-omics provides the consensus-scored POLR3GP2 profile across patient tissues and cancer cell-line models. POLR3GP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, POLR3GP2 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, POLR3GP2 RNA expression shows 5,595 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight THCA, HNSC, and UCEC as cancer lineages where POLR3GP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3GP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3GP2 survival associations across molecular data types. POLR3GP2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3GP2 RNA expression–survival associations across cancer types. High POLR3GP2 expression shows unfavorable associations in THCA, KICH, READ, MESO, UCEC and KIRC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for POLR3GP2 RNA expression.
This table summarizes POLR3GP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for POLR3GP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3GP2 shows higher tumor expression in HNSC, BRCA and LUAD. The HNSC box plot shows higher POLR3GP2 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .007).
This table shows molecular features associated with POLR3GP2 in patient tissues and cancer cell lines. In patient samples, POLR3GP2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
